RankingsPricing
  1. US-listed companies
  2. Dare Bioscience, Inc.

Dare Bioscience, Inc.DARE

Market cap
$331.17M
P/E ratio
Back to summarized table
Income statementBalance sheetCash flow
Dec 31,
2014		Dec 31,
2015		Dec 31,
2016		Dec 31,
2017		Dec 31,
2018		Dec 31,
2019		Dec 31,
2020		Dec 31,
2021		Dec 31,
2022
Net loss-23-40-39-11,503,117-16,738,815-14,263,830-27,400,743-39-31
Depreciation----2,44011,13743,22726,41324,202
Stock-based compensation12315,832139,348462,239742,03122
Non-Cash Lease Expense------29,121-162,167-96,13223,415
Gain on early termination of lease--------0
Non-cash loss on settlement of contingent liability-------44,286-
Gain on extinguishment of note payable and accrued interest-2------369,887-
Other receivables----662,059-253,169201,423-95,042685,149557,842
Prepaid expenses---113,02191,526322,482454,133622,3364
Other non-current assets---2,800-145,223-237,937-157,725-20,873-3,650
Accounts payable01-1-151,486608,650-61,8501-75,132
Accrued expenses13-1--27,083621,6181-45,8718
Deferred grant funding-----238,109455,121-8,978,430-7,760,584
Net cash used in operating activities-----10,268,425-13,315,480-25,234,924-28,764,037-18,088,429
Purchases of property and equipment001-11,836-17,62514,52463,069
Net cash used in investing activities-----518,8366-17,625-14,524-63,069
Net proceeds from issuance of common stock-------751
Proceeds from the exercise of common stock warrants----1052500,146-
Proceeds from Stock Options Exercised------132,529124,604
Net cash provided by financing activities----10525761
Effect of exchange rate changes on cash and cash equivalents------5,89711,237-63,585-196,338
Net change in cash and cash equivalents------2,025,782-110,64047-17,004,482
Right-of-Use Asset Obtained in Exchange for Operating Lease Liability-----583,697-308,533585,942
Milestone Payments, Contingent Amount-------250,000-